Optos Announcements

RNS Number : 2810H Optos plc 03 November 2008  
?
OPTOS PLC
("Optos" or the "Company" or the "Group")
Total Voting Rights and Issued Share Capital
LONDON - 03 November 2008: Optos plc (LSE: OPTS) confirms that, in accordance with the provisions of the Financial Services Authority's ("FSA") Disclosure and Transparency Rules ("DTR" or the "Rules"), as at 31 October 2008, the Company had an issued share capital of 69,527,475 Ordinary Shares of £0.02 per share which are admitted to trading and which carry the right to one vote at general meetings of the Company. The Company holds no shares in treasury. Therefore, the total number of voting rights in the Company is 69,527,475. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Optos plc under the FSA's Disclosure and Transparency Rules. 

Enquiries

Optos plc
Barbara Gubbins, 
Company Secretarial Assistant
+44 (0)1383 843 359

Maitland
Brian Hudspith
+44 (0)20 7379 5151

About Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to detect clinically with conventional examination equipment and techniques. Optos' devices produce ultra wide-field, high resolution images of approximately 82% of the retina, something no other device is capable of doing in any one image. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. Optos has a range of medical devices that support different customer segments and patient levels: P200 device is concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; P200C device is designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; P200MA device supports retinal specialists, working primarily with a diabetic patient base, in the medical care market through an advanced medical angiography procedure. Optos' technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for the practitioner and patient resulting in more targeted treatment regimes and improved patient outcomes. This can help save sight and save lives. Optos estimates that it is addressing a market opportunity with a combined $4 billion potential. 
Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNSThe company news service from the London Stock Exchange  END  TVRUUGBUGUPRGGW